How to Qualify for GLP-1 Medications: BMI, Conditions & More

GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) have transformed the medical management of obesity and type 2 diabetes. Clinical trials have demonstrated weight loss outcomes previously achievable only through bariatric surgery—making these medications among the most significant advances in obesity medicine in decades. But knowing how to qualify for GLP-1 medications is the essential first step before starting treatment.

The qualification criteria for GLP-1 medications are based on FDA-approved indications, clinical guidelines, and—for insurance coverage purposes—specific insurer requirements. While the criteria are fairly well-defined, many patients are surprised to learn they qualify even without a diabetes diagnosis, or conversely, that they need additional documentation or prior history to gain insurance approval.

This guide explains exactly what clinicians and insurance companies look for when evaluating patients for GLP-1 therapy: BMI thresholds, qualifying comorbidities, contraindications, and what to expect during a clinical evaluation. Understanding these criteria before your consultation puts you in the best position to access treatment efficiently.

FDA-Approved Indications: The Starting Point

The FDA has approved GLP-1 medications for two primary indications, each with different qualifying thresholds:

Type 2 Diabetes Management: Ozempic (semaglutide 0.5–2mg) and Mounjaro (tirzepatide) are FDA-approved as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes. There are no BMI requirements for this indication—if a physician determines GLP-1 therapy is appropriate for your diabetes management, you may qualify regardless of weight.

Chronic Weight Management: Wegovy (semaglutide 2.4mg) is FDA-approved for chronic weight management in adults with an initial BMI of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) with at least one weight-related comorbidity. Zepbound (tirzepatide) carries the same BMI thresholds for its obesity indication. This indication specifically requires meeting both the weight threshold and, for the 27+ BMI group, an associated medical condition.

Understanding which indication applies to your situation shapes how your clinician will structure your prescription and how insurers will evaluate coverage requests.

BMI Requirements Explained

Body Mass Index (BMI) is the primary anthropometric threshold for GLP-1 qualification for weight management. Here's how the numbers break down:

BMI ≥ 30 (Obesity): Patients with a BMI of 30 or higher qualify for GLP-1 weight management medications based on BMI alone, without needing any additional diagnosed comorbidity. At this level, the health risks of excess weight—including cardiovascular disease, sleep apnea, joint problems, and metabolic dysfunction—are well-established enough that treatment is medically justified on its own merits.

BMI 27–29.9 (Overweight with Comorbidity): Patients in this range qualify if they also have at least one weight-related health condition. This threshold reflects the clinical reality that excess weight causes disproportionate harm in the presence of certain medical conditions, even at BMI levels below the formal obesity threshold.

BMI Below 27: GLP-1 medications are generally not prescribed for weight loss at BMI levels below 27 outside of very specific clinical circumstances. Patients in this range are typically not candidates for these medications for weight management purposes.

It's worth noting that BMI has limitations as a sole measure of metabolic health. Clinicians may also consider waist circumference, body composition, and other metabolic markers when evaluating appropriateness of treatment. Some patients at BMI 26–27 with significant visceral adiposity and multiple metabolic risk factors may still be evaluated as appropriate candidates at clinical discretion.

Weight-Related Comorbidities That Qualify

For patients with a BMI between 27 and 29.9, at least one of the following weight-related comorbidities is required to qualify for GLP-1 weight management therapy under FDA-approved indications:

• Type 2 diabetes or prediabetes – including impaired fasting glucose or impaired glucose tolerance
• Hypertension – elevated blood pressure (≥130/80 mmHg) or being treated with antihypertensive medication
• Dyslipidemia – abnormal cholesterol or triglyceride levels, including elevated LDL, low HDL, or hypertriglyceridemia
• Obstructive sleep apnea – diagnosed by sleep study
• Cardiovascular disease – including coronary artery disease, heart failure, or prior cardiac events
• Metabolic syndrome – cluster of metabolic risk factors including abdominal obesity, insulin resistance, dyslipidemia, and hypertension
• Non-alcoholic fatty liver disease (NAFLD/NASH) – increasingly recognized as a weight-related condition justifying treatment
• Osteoarthritis – weight-related joint disease, particularly of the knees and hips

Many patients with a BMI of 27–29 are surprised to discover they have one or more of these conditions—sometimes undiagnosed—that would qualify them for treatment. A thorough clinical evaluation at Truventa Medical can identify qualifying comorbidities that support your treatment request.

Contraindications: Who Should Not Take GLP-1 Medications

Understanding what disqualifies a patient is just as important as understanding qualifying criteria. GLP-1 medications have established contraindications and precautions that clinicians evaluate during the intake process:

Personal or family history of medullary thyroid carcinoma (MTC): GLP-1 receptor agonists carry a black box warning regarding thyroid C-cell tumors observed in rodent studies. While human clinical significance remains under study, patients with a personal or family history of MTC should not take these medications.

Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): This rare genetic condition that predisposes to thyroid and other endocrine tumors is a contraindication.

Severe gastrointestinal conditions: Patients with gastroparesis or other significant GI motility disorders may not be appropriate candidates, given GLP-1 medications' mechanism of slowing gastric emptying.

Pancreatitis history: A history of pancreatitis warrants careful evaluation, though it is not an absolute contraindication in all clinical contexts.

Pregnancy or planned pregnancy: GLP-1 medications should be discontinued prior to conception and are not recommended during pregnancy. Women of childbearing potential should discuss contraception.

Type 1 diabetes: GLP-1 medications are not FDA-approved for type 1 diabetes management, though some off-label use occurs in clinical contexts under careful monitoring.

What the Clinical Evaluation Process Involves

Qualifying for GLP-1 medications isn't purely a matter of meeting numerical thresholds—it involves a clinical evaluation by a licensed healthcare provider who reviews your full health picture and determines whether treatment is appropriate and safe for you specifically.

At Truventa Medical's weight loss program, the evaluation typically includes:

Medical history review: Including current and past diagnoses, medications, allergies, surgical history, and family history of conditions that may affect eligibility.

Current measurements: Weight, height, and BMI calculation. Some programs also request waist circumference or recent lab work.

Comorbidity assessment: Review of any diagnosed or suspected weight-related health conditions that may support qualification or affect medication selection.

Contraindication screening: Systematic review of conditions or medications that might preclude safe use.

Goal-setting and expectations: Discussion of realistic treatment outcomes, the importance of lifestyle integration, and long-term treatment planning.

The entire evaluation can take place remotely via telehealth—no in-office visit required. If a clinician determines you qualify, a prescription may be issued the same day.

Age Requirements and Special Populations

GLP-1 medications for weight management are approved for adults (18 years and older) in most clinical contexts. However, Wegovy has received FDA approval for adolescents aged 12 and older with obesity, reflecting the growing recognition of pediatric obesity as a serious medical condition requiring treatment.

For older adults, GLP-1 medications are generally appropriate but require additional attention to muscle mass preservation, since weight loss in older patients can accelerate sarcopenia. Clinicians may recommend higher protein intake and resistance exercise as adjuncts to minimize lean tissue loss.

Patients with chronic kidney disease (CKD) or moderate hepatic impairment can generally use these medications, though dose adjustments may be considered in more advanced disease states. Patients on insulin or sulfonylureas for diabetes need careful monitoring for hypoglycemia when adding a GLP-1 agent.

Does Previous Weight Loss Treatment Matter?

For insurance coverage purposes, many plans require documentation of previous weight loss attempts before approving GLP-1 therapy. This "step therapy" requirement typically asks for evidence of participation in a structured diet and exercise program, behavioral counseling, or use of prior weight loss medications.

From a pure clinical standpoint (setting insurance requirements aside), there is no medical prerequisite that patients must have tried and failed other interventions before beginning GLP-1 therapy. Clinical guidelines from the American Society of Metabolic and Bariatric Surgery and the Obesity Society support using effective pharmacotherapy earlier in the treatment course, rather than requiring patients to exhaust less effective approaches first.

That said, GLP-1 medications work best when combined with dietary changes and increased physical activity. Clinicians will typically discuss lifestyle integration as part of the treatment plan, not because it's a prerequisite to medication, but because it significantly enhances outcomes.

Next Steps: How to Get Evaluated

If you believe you meet the criteria described above—or simply want a professional evaluation—the process through telehealth is straightforward and can often be completed within 24 hours. You don't need a referral or an in-office visit to get started.

Through Truventa Medical, you'll complete a brief health intake form, which our licensed clinicians review to determine whether you qualify for GLP-1 therapy and which medication may be most appropriate for your situation. If approved, your prescription is sent to a licensed pharmacy with convenient home delivery. Start your free consultation today and take the first step toward evidence-based weight management care.